# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4119683

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	

## **CONVEYING PARTY DATA**

Name	Execution Date
EUTHYMICS BIOSCIENCE, INC.	03/02/2015

## **RECEIVING PARTY DATA**

Name:	NEUROVANCE, INC.
Street Address:	43 THORNDIKE STREET
Internal Address:	SUITE S1-3
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02141

## **PROPERTY NUMBERS Total: 17**

Property Type	Number
Application Number:	11493431
Application Number:	12334432
Application Number:	13207199
Application Number:	13366219
Application Number:	13887367
Application Number:	14494512
Application Number:	14929361
Application Number:	13221892
Application Number:	13425371
Application Number:	13669438
Application Number:	13856431
Application Number:	14802802
Application Number:	13334066
Application Number:	13528940
Application Number:	13751169
Application Number:	13907921
Application Number:	11936016

## **CORRESPONDENCE DATA**

**Fax Number:** (973)912-5236

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** (973)912-5232

Email: FILE@HOXPAT.COM

Correspondent Name: HOXIE & ASSOCIATES LLC

Address Line 1: 75 MAIN STREET

Address Line 2: SUITE 203

Address Line 4: MILLBURN, NEW JERSEY 07041

ATTORNEY DOCKET NUMBER:	EB-11, 12, 16, 19
NAME OF SUBMITTER:	MARYA K. JONES
SIGNATURE:	/Marya K. Jones/
DATE SIGNED:	10/28/2016

#### **Total Attachments: 7**

source=Second Euthymics to Neurovance Assignment#page1.tif source=Second Euthymics to Neurovance Assignment#page2.tif source=Second Euthymics to Neurovance Assignment#page3.tif source=Second Euthymics to Neurovance Assignment#page4.tif source=Second Euthymics to Neurovance Assignment#page5.tif source=Second Euthymics to Neurovance Assignment#page6.tif source=Second Euthymics to Neurovance Assignment#page7.tif

#### ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT OF PATENT RIGHTS is made effective the 22nd day of December, 2011, by and between EUTHYMICS BIOSCIENCE. INC., a Delaware corporation (the "Assignor"), and NEUROVANCE, INC., a Delaware corporation (the "Assignee").

WHEREAS, the Assignor is the holder of the exclusive right, title and interest in and to the patent rights (the "Patent Rights") listed on Appendix "A" hereto;

WHEREAS, the Assignor and the Assignee desire that the Assignor transfer the entire and exclusive right, title and interest in and to the Patent Rights;

NOW, THEREFORE, in consideration of the premises, the parties agree as follows:

In consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged. Assignor has assigned and transferred and does hereby assign and transfer to the Assignee and its successors, assigns, and nominees, as the assignee, without any restrictions, reservations or limitations:

- (a) the entire and exclusive right, title and interest in said Intellectual Property, including, but not limited to, the Patent Rights and all Letters Patents which may be granted thereon, and all patent applications and Letters Patents that claim priority therefrom or common priority therewith, under the patent laws of any country of the world, including all divisions and continuations thereof, and all reissues, reexaminations, substitutions, registrations, renewals, extensions, and Supplementary Protection Certificates or the like thereof; and
- (b) the sole right to file applications for patents under the patent laws of any country of the world in its name, and the sole right to have patents granted on said applications in its name to the full end of term for which said patents may be granted, as fully and entirely as the same would have been held by Assignor, had this assignment not been made, and to enforce said patents with the right to sue for and recover for its own use accrued profits or damages for any and all infringements with respect to which Assignor hereby waives any right to receive any portion thereof.

The Assignor hereby authorizes and requests that Patent Officials in the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, recognize Neurovance, Inc., as the assignee of Assignor's entire right, title and interest in and to the same, for the sole use and enjoyment of Neurovance, Inc., its successors and assigns.

IN TESTIMONY WHEREOF, I. Anthony A. McKinney, the President and Chief Executive Officer of Euthymics Bioscience, Inc., have hereunto set my hand this 2nd day of March, 2015.

#### EUTHYMICS BIOSCIENCE, INC.,

a Delaware corporation

By:
Anthony A. McKinney. President and Chief
Executive Officer

COMMONWEALTH OF MASSACHUSETTS	Ole:	
	John J.	SS
COUNTY OF MIDDLESEX	dia.	

Before me, a Notary Public in and for said County and State, on this 2nd day of March, 2015, personally appeared Anthony A. McKinney, to me known to be the identical person who executed the foregoing Assignment and acknowledged to me that he executed the same as his free and voluntary act and deed for the purposes therein set forth.

Notary Public Commission No:

My Commission Expires: 10/6/17

## APPENDIX A

APPLICATION NUMBER	COUNTRY	TITLE
2006275870	Australia	NOVEL 1-ARYL-3-
	980 000 000 000 000 000 000 000 000 000	AZABICYCLO[3.1.0]HEXANES:
er volugiones	Elegandro de Control d	PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
PI0613943-4	Brazil	NOVEL 1-ARYL-3-
	Popularia	AZABICYCLO[3.1.0]HEXANES:
eryci.		PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
2,659,215	Canada	NOVEL 1-ARYL-3-
70° - 10° -	-79)006	AZABICYCLO[3.1.0]HEXANES:
	***************************************	PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
200680035426.4	China	NOVEL 1-ARYL-3-
		AZABICYCLO[3.1.0]HEXANES:
	eser in the control of the control o	PREPARATION AND USE TO TREAT
	Market and the last of the same and the same	NEUROPSYCHIATRIC DISORDERS
06788541.8	Europe	NOVEL 1-ARYL-3-
PP-Y-Lindon	d) who have a second	AZABICYCLO[3.1.0]HEXANES:
Merchanism	de la companya de la	PREPARATION AND USE TO TREAT
001110000		NEUROPSYCHIATRIC DISORDERS
08111850.8	Hong Kong	NOVEL 1-ARYL-3-
	Wednesday	AZABICYCLO[3.1.0]HEXANES:
	Victoria	PREPARATION AND USE TO TREAT
76117577 0	P. W. W.	NEUROPSYCHIATRIC DISORDERS
08113526.8	Hong Kong	NOVEL 1-ARYL-3-
	numper of	AZABICYCLO[3.1.0]HEXANES:
	1	PREPARATION AND USE TO TREAT
1738/DELNP/2008	India	NEUROPSYCHIATRIC DISORDERS
1750/DEBNE/2000	mana	NOVEL I-ARYL-3-
		AZABICYCLO[3.1.0]HEXANES:
	ļ	PREPARATION AND USE TO TREAT
W00200800242	Indonesia	NEUROPSYCHIATRIC DISORDERS
	mouncsia	NOVEL 1-ARYL-3- AZABICYCLO[3.1.0]HEXANES;
		PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
189008	Israel	NOVEL 1-ARYL-3-
	J. L78 6 942 9	AZABICYCLO[3.1.0]HEXANES:
	Barray profit	PREPARATION AND USE TO TREAT
	· ·	NEUROPSYCHIATRIC DISORDERS
		AVERTAL OF THE THE ATTENDED TO

APPLICATION NUMBER	COUNTRY	TITLE
2008-524100	Japan	NOVEL 1-ARYL-3-
	-	AZABICYCLO[3.1.0]HEXANES:
	- Carlos	PREPARATION AND USE TO TREAT
	and the second	NEUROPSYCHIATRIC DISORDERS
1020087004765	Korea	NOVEL 1-ARYL-3-
	Second Ald Second	AZABICYCLO[3.1.0]HEXANES:
	et de la companya de	PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
Mx/a/2008/001187	Mexico	NOVEL 1-ARYL-3-
		AZABICYCLO[3.1.0]HEXANES:
To a service of the s		PREPARATION AND USE TO TREAT
recodercity		NEUROPSYCHIATRIC DISORDERS
566236	New	NOVEL I-ARYL-3-
	Zealand	AZABICYCLOJ3.1.0JHEXANES:
		PREPARATION AND USE TO TREAT
	-36-36-96-9	NEUROPSYCHIATRIC DISORDERS
592836	New	NOVEL 1-ARYL-3-
	Zealand	AZABICYCLO[3.1.0]HEXANES:
	Zearand	PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
20081016	Norway	NOVEL 1-ARYL-3-
	Evolway	±
		AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT
PCT/US2006/029006		NEUROPSYCHIATRIC DISORDERS
7 C C C C C C C C C C C C C C C C C C C	To all made and	NOVEL 1-ARYL-3-
		AZABICYCLO[3.1.0]HEXANES:
		PREPARATION AND USE TO TREAT
12008500187	Philippines	NEUROPSYCHIATRIC DISORDERS
(2000)0(7:0)	rumpanes	NOVEL 1-ARYL-3-
	and the segret	AZABICYCLO[3.L0]HEXANES:
	11.044.610	PREPARATION AND USE TO TREAT
2008107336	Russia	NEUROPSYCHIATRIC DISORDERS
2008107330	Kussia	NOVEL 1-ARYL-3-
		AZABICYCLO[3.1.0]HEXANES:
	100	PREPARATION AND USE TO TREAT
200800684-3	Cincon	NEUROPSYCHIATRIC DISORDERS
200800084-3	Singapore	NOVEL 1-ARYL-3-
	CONTRACTOR OF THE CONTRACTOR O	AZABICYCLO[3.1.0]HEXANES:
	The state of the s	PREPARATION AND USE TO TREAT
2008/01825		NEUROPSYCHIATRIC DISORDERS
MU0:U102.)	South Africa	NOVEL 1-ARYL-3-
	and the state of t	AZABICYCLO[3.1.0]HEXANES:
		PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS

APPLICATION NUMBER	COUNTRY	TITLE
60/703,364	U.S.	NOVEL 1-ARYL-3-
e distribution		AZABICYCLO[3.1.0]HEXANES:
Earthy John	H popular	PREPARATION AND USE TO TREAT
Total Control		NEUROPSYCHIATRIC DISORDERS
11/493,431	U.S.	NOVEL 1-ARYL-3-
	A Property Character Control of the	AZABICYCLO[3.1.0]HEXANES:
ERR CONCESS		PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
12/334,432	U.S.	NOVEL 1-ARYL-3-
		AZABICYCLO[3.1.0]HEXANES:
		PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
13/207,199	U.S.	NOVEL 1-ARYL-3-
time dryp	the state of the s	AZABICYCLO[3.1.0]HEXANES:
	75 300	PREPARATION AND USE TO TREAT
		NEUROPSYCHIATRIC DISORDERS
PI0718654-1	Brazil	NOVEL.
- Control of the cont	Washington (Co.)	ARYLBICYCLO[3.1.0]HEXYLAMINES AND
	(connection of the connection	METHODS AND COMPOSITIONS FOR THEIR
		PREPARATION AND USE
2,705,457	Canada	NOVEL
		ARYLBICYCLO[3.1.0]HEXYLAMINES AND
		METHODS AND COMPOSITIONS FOR THEIR
		PREPARATION AND USE
07861821.2	Europe	NOVEL
		ARYLBICYCLO[3.1.0]HEXYLAMINES AND
		METHODS AND COMPOSITIONS FOR THEIR
		PREPARATION AND USE
3695/DELNP/2009	India	NOVEL
	TO THE STATE OF TH	ARYLBICYCLO[3.1.0]HEXYLAMINES AND
		METHODS AND COMPOSITIONS FOR THEIR
2000 72 520		PREPARATION AND USE
2009-536293	Japan	NOVEL
		ARYLBICYCLO[3.1.0]HEXYLAMINES AND
	On the second	METHODS AND COMPOSITIONS FOR THEIR
100000000000000000000000000000000000000	**************************************	PREPARATION AND USE
1020097011844	Korea	NOVEL
		ARYLBICYCLO[3.1.0]HEXYLAMINES AND
	***************************************	METHODS AND COMPOSITIONS FOR THEIR
BOTH BOARDAWAS FOR		PREPARATION AND USE
PCT/US2007/023506	(gd.ampool)	NOVEL
		ARYLBICYCLO[3.1.0]HEXYLAMINES AND
	Education and the second secon	METHODS AND COMPOSITIONS FOR THEIR
***************************************	1	PREPARATION AND USE

APPLICATION NUMBER	COUNTRY	TITLE
2009121553	Russia	NOVEL ARYLBICYCLO[3.1,0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
2009/03935	South Africa	
60/857,667	U.S.	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
11/936,007	U.S.	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
11/936,016	U.S.	NOVEL ARYLBICYCLO[3, L0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
11/936,722	U.S.	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
08768192.0	Europe	NOVEL 1-HETEROARYL-3- AZABICYCLO[3, 1,0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
10108387.2	Hong Kong	NOVEL 1-HETEROARYL-3- AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
PCT/US2008/007116		NOVEL 1-HETEROARYL-3- AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
60/933,631	U.S.	NOVEL 1-HETEROARYL-3- AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
12/135,053	U.S.	NOVEL 1-HETEROARYL-3- AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

APPLICATION NUMBER	COUNTRY	TITLE
12/895,788	U.S.	NOVEL 1-HETEROARYL-3- AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
13/048,852	U.S.	NOVEL 1-HETEROARYL-3- AZABICYCLO[3.1.0]HEXANES, MFTHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
13/221.892	U.S.	NOVEL 1-HETEROARYL-3- AZABICYCLO[3.1.0]HEXANES. METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
61/574,231	Los. S.	USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)- 3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
13/334,066	U.S.	USE OF (1R,58)-(+)-1-(NAPHTHALEN-2-YL)- 3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS

5